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Abstract 
Primary Sjögren’s syndrome (pSS) is a systemic autoimmune disease, characterized by lymphocytic 
infiltration of the secretory glands. This process leads to sicca syndrome, which is the combination 
of dryness of the eyes, oral cavity, pharynx, larynx and/or vagina. Extraglandular manifestations may 
also be prevalent in patients with pSS, including cutaneous, musculoskeletal, pulmonary, renal, 
hematological and neurological involvement. The pathogenesis of pSS is currently not well 
understood, but increased activation of B cells followed by immune complex formation and 
autoantibody production are thought to play important roles. pSS is diagnosed using the 
American-European consensus group (AECG) classification criteria which include subjective 
symptoms and objective tests such as histopathology and serology. The treatment of pSS warrants 
an organ based approach, for which local treatment (teardrops, moistures) and systemic therapy 
(including non-steroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, disease-modifying 
antirheumatic drugs (DMARDS) and biologicals) can be considered. Biologicals used in the 
treatment of pSS mainly affect the total numbers of B cells (B cell depletion (Rituximab)) or target 
proteins required for B cell proliferation and/or activation (e.g. B cell activating factor (BAFF)) 
resulting in decreased B cell activity.  
The aim of this review is to provide physicians a general overview concerning the pathogenesis, 
diagnosis and management of pSS patients. 
Key words: primary Sjögren syndrome, sicca, extraglandular syndrome, biologicals, epidemiology, 
pathogenesis, T-cell, B-cell. 
Introduction 
Sjögren’s syndrome (SS) is a relatively common 
systemic autoimmune disease characterized by 
lymphocytic infiltration of the secretory glands. This 
process leads to sicca syndrome, which is the 
combination of dryness of the eyes, oral cavity, 
pharynx, larynx and/or vagina [1]. Sicca syndrome is 
often accompanied by symptoms resulting from 
systemic involvement. SS can be present as a primary 
disease without any other accompanying symptoms 
(primary Sjögren syndrome, pSS). When SS presents 
as a secondary disease with other autoimmune 
diseases such as systemic lupus erythematosus (SLE), 
rheumatoid arthritis (RA) and systemic sclerosis, it is 
then called secondary SS (sSS) [2, 3]. The prevalence of 
sSS is highest in RA patients and estimated to be 
around 20% [2, 4].  
In this review we will focus on pSS. The 
incidence of pSS is estimated to be 4 per 1000 patients 
per year and overall prevalence of pSS in Europe is 
between 0.1-4.8% [5, 6]. However, as many symptoms 
are non-specific, the prevalence may be 
underestimated.  
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Pathogenesis 
The pathogenesis of pSS is incompletely 
understood but appears to be multifactorial. Although 
T cells were originally considered to be the key 
players in the autoimmune process, there is now 
growing evidence that B cells play at least an equally 
important role in the pathophysiology of pSS (Figure 
1). In the next section we will discuss in more detail 
the known and potential roles of the different immune 
cells in the pathogenesis of pSS. 
 
 
Figure 1. Schematic showing a simplified overview of the pathogenesis of pSS 
with the targets for biologicals. An unknown cause (suggested to be a virus or 
immune complexes) may lead to activation of pDCs resulting in increased levels 
of interferons. Interferon-induced BAFF production leads to increased B cell 
proliferation and differentiation with autoantibody production as result. 
Abbreviations: pDC, plasmacytoid dendritic cell; Th1, T-helper 1 cell; IFN, 
interferon; B, B cell; PC, Plasma cell; Tfh, Follicular T-helper cell. 
 
T cells in pSS 
The presence, and sometimes predominance, of 
CD4+ T cells in salivary gland infiltrates underlines 
their potential contribution to the pathogenesis of pSS 
[7]. A meta-analysis showed the association between 
pSS and several major histocompatibility complex 
class 2 (MHC2) alleles suggesting that autoantigen 
presentation is important in the pathogeneses of pSS 
[8]. Th1 cells are hypothesized to be the main subtype 
contributing to pathogenesis, since they bind to the 
MHC2 molecules initiating an immune response. In 
addition, pro-inflammatory Th1 cell cytokines (e.g. 
IL-1b, IL-6, tumor necrosis factor-α and interferon-γ) 
are increased in saliva of patients with pSS [9]. 
Furthermore, a study in 2009 reported a pSS-like 
syndrome in mice with IL-12 overexpression, which is 
known to induce Th1 cell differentiation [10]. Besides 
Th1 cells, the numbers of T helper 17 (Th17) cells are 
also increased at sites of inflammation in salivary 
gland biopsies of pSS patients [11]. IL-17, produced by 
Th17 cells, is increased in both serum and salivary 
glands of patients with pSS as compared to healthy 
controls [12]. Co-expression of IL-17 and IL-18 has 
been associated with increased severity of pSS, 
probably due to maintaining the inflammatory 
process [11, 13]. Furthermore, regulatory T cells (Treg) 
have been identified in salivary glands of pSS patients 
and the increased presence of these cells has been 
associated with higher grade of inflammation in the 
local lesions [14, 15]. Tregs are known to have 
suppressive effects on the proliferation and function 
of effector T cells. It has been reported that the 
number of circulating Tregs are increased, while their 
function does not seem to be impaired in pSS, which 
suggests that Tregs do not play an important role in 
the pathogenesis of pSS [16]. 
B cells in pSS 
B cells are adaptive immune cells and are 
responsible for antibody secretion and antigen 
presentation. B cell development occurs in the bone 
marrow. One of the key factors in this process is B cell 
activating factor (BAFF). BAFF is a cytokine that 
promotes B cell proliferation, maturation and survival 
and is primarily induced by type I and type II 
interferons [17, 18]. These interferons are produced by 
plasmacytoid dendritic cells (pDCs) [13, 19]. It has 
been suggested that certain viruses (e.g. Epstein-Barr) 
and immune complex formation activate Toll-like 
receptors (TLRs) (e.g. TLR 3, 7 and 9), leading to 
activation of the innate immunity and interferon 
production. Although an increased activity of TLRs 
has been reported in pSS, a specific cause (virus or 
immune complex) has not yet been identified [20, 21]. 
In pSS patients, 55% have an increased IFN type I 
activity versus 4.5% in healthy controls [22]. The 
presence of this so-called ‘IFN type I signature’ in 
monocytes of patients with pSS was shown to be 
associated with higher EULAR Sjögren's Syndrome 
Disease Activity Index (ESSDAI), the presence of 
biological markers of activity (increased levels of IgG 
and/or hypocomplementia) and increased levels of 
BAFF mRNA in monocytes [22]. Circulating and 
salivary gland tissue levels of BAFF are significantly 
elevated in patients with pSS, which is associated with 
increased disease activity but also with higher risk of 
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development of B cell lymphoma [23-25]. These 
findings support the hypothesis that innate immune 
system activation leads to an autoimmune response 
by the adaptive immune system. Since BAFF is one of 
the links between innate and adaptive immune 
responses, it could be a potential target for therapy in 
pSS. The first results of studies on anti-BAFF therapy 
(belimumab) show a significant decrease in disease 
activity after twelve months of treatment as measured 
by the ESSDAI [26]. Upon antigen recognition in the 
germinal center, B cells proliferate and differentiate 
(e.g. class switching) into a specific B cell for this 
antigen [27]. In pSS, germinal centers are reported in 
the epithelium of non-lymphoid tissues such as the 
salivary glands [28]. The formation of germinal 
centers is probably important in the pathogenesis of 
pSS due to promotion of chronic stimulation and 
activation (by follicular T helper cells) of B cells. 
Patients with pSS often present with high levels of 
serum IgA and/or IgG [29]. Hyperglobulinemia may 
lead to the formation of immune complexes with the 
potential to precipitate in major organs leading to 
(irreversible) damage [30]. In addition, the presence of 
autoantibodies (anti-Ro52, anti-Ro60 and anti-La) is 
included in the diagnostic criteria for pSS [31, 32]. The 
presence of these autoantibodies is associated with 
early onset disease, parotid gland enlargement, 
extraglandular manifestations and lymphocytic 
glandular infiltration [13, 33].  
In sum, it remains unclear how these changes in 
the adaptive immune system lead to the clinical 
manifestations of pSS. The traditional view that 
chronic inflammation results in tissue destruction of 
the exocrine glands will only partially contribute to 
the pathogenesis of pSS. There is a poor correlation 
between the amount of damage observed in tissue 
biopsies and the measured decrease in fluid 
production, as the reduction in salivary production is 
often larger than expected from both clinical and 
histological appearance [34].  
Clinical presentation 
There is not a standard clinical presentation for 
pSS, as many patients have various degrees of 
systemic involvement at the time of presentation. The 
symptoms of pSS can be divided into three groups, (1) 
sicca syndrome, (2) general symptoms and (3) 
systemic manifestations. 
Sicca syndrome 
Sicca syndrome is the combination of dryness of 
the eyes (xeropthalmia), oral cavity (xerostomia), 
pharynx and/or larynx, which are the classical 
symptoms of pSS. In woman, also vaginal dryness is a 
common feature of pSS [35]. These symptoms are part 
of the American-European classification criteria 
(AECG) of 2002 for the diagnosis pSS and occur in 
more than 95% of patients [31]. The positive 
predictive value of the AECG criteria is between 
54-77% and the negative predictive value is between 
94-98% as compared to the classification criteria of 
1986 [31]. Xerostomia may lead to secondary 
problems like oral candidiasis (33%), dental carries 
(65%) and periodontal disease [36, 37]. Xerophtalmia 
may result in photosensitivity, chronic irritation and 
destruction of the corneal epithelium and ocular 
infections. Additionally, sicca syndrome also includes 
hoarseness, non-productive cough, skin dryness and, 
in woman, dyspareunia [38, 39]. Patients with pSS 
experience a significantly decreased quality of life 
compared to subjects with sicca syndrome without 
autoimmune features as measured by the SF-36 
depression scale [40, 41]. 
General symptoms 
The most prevalent general symptom is fatigue, 
occurring in up to 70-80% of pSS patients [42]. Fatigue 
in pSS has been well studied using the 
multidimensional fatigue inventory (MFI) on which 
pSS patients scores were two-fold worse on all 
dimensions as compared to healthy controls [43, 44]. 
In addition, chronic pain is often seen in pSS due to 
accompanying fibromyalgia and/or polyarthralgia 
[45]. Depression and anxiety are also more common in 
pSS patients compared to healthy controls [46]. A 
study showed that 47% of the working age pSS 
patients received disability compensation, because 
they were considered to be (partially) unfit for work 
[47]. The same study also reports that significantly 
more patients with the following 
demographic/disease characteristics receive 
disability compensation: male patients, patients with 
a high educational level, an increasing number of 
systemic manifestations and/or the use of artificial 
saliva and/or HCQ [40, 41, 47]. 
Systemic manifestations 
Approximately 71% of the patients with pSS 
present with extraglandular manifestations [48] 
(Table 1). Of those, lymphoma has the highest 
mortality [49]. A large cohort study reported a nearly 
5-fold higher relative risk in pSS patients with a 
life-time risk of approximately 10% [50, 51]. The most 
common subtype is the mucosa-associated lymphoid 
tissue (MALT) lymphoma often seen in the parotid 
glands, which is usually a low-grade indolent 
neoplasm [52, 53]. Clinical risk factors include 
persistent, unilateral salivary gland enlargement, 
lymphadenopathy, splenomegaly, skin vasculitis, 
cryoglobulinemia and the development of 
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glomerulonephritis [54, 55]. Laboratory-assessed 
biological risk factors for lymphoma in pSS include 
cryoglobulinemia, lymphopenia (especially low total 
numbers of CD4+ T cells), hypocomplementia, 
increased serum BAFF and the presence of a 
monoclonal component in serum or urine [27, 54, 56]. 
Articular involvement in pSS predominantly consists 
of symmetric, intermittent, nonerosive arthropathy 
[57, 58]. Arthritis is less common and occurs in 
approximately 16% of pSS patients and mostly 
involves proximal interphalangeal joints (35%), 
metacarpal-phalangeal joints (35%) and wrists (30%) 
[58, 59]. Approximately 10-20% of pSS patients 
develop interstitial lung disease (ILD)[60]. In general, 
patients will have evidence of both airway disease 
and ILD by radiographs (plain X-ray and/or CT-scan) 
and pulmonary biopsy [60]. Another study reported 
that patients with pSS who do not have pulmonary 
symptoms already may have radiographic or 
computed tomography (CT) scan abnormalities (22%) 
or an impaired pulmonary function test [61]. The most 
frequently observed CT patterns consist of interstitial 
pneumonia, centrilobular abnormalities and 
lymphoproliferative disease [61]. This emphasizes 
that a frequent pulmonary function test or a 
high-resolution CT-scan should be performed in the 
follow-up of pSS patients with and without 
pulmonary complaints. The most common 
histopathological phenotype of ILD in pSS is 
nonspecific interstitial pneumonia (NSIP), which has 
been reported in approximately 45% of the pSS 
patients with ILD [62, 63]. ILD is difficult to treat and 
results in an increase of dry cough and dyspnea, 
leading to decreased quality of life. ILD is usually 
treated with glucocorticoids but other 
immunosuppressive drugs are also available, such as 
azathioprine, mycophenolate mofetil, 
cyclophosphamide and cyclosporine [64, 65]. 
Furthermore, renal involvement is common and 
includes a wide spectrum of manifestations, of which 
interstitial nephritis is the most prevalent [66, 67]. 
Consistent screening for renal function is important 
since renal failure (defined as a glomerular filtration 
rate < 60 ml/min) occurs in approximately 24% of the 
pSS patients [68]. There is no standardized treatment 
of renal involvement in pSS. Glucocorticoids are the 
treatment of first choice in tubulointerstitial nephritis, 
whereas other immunosuppressive drugs are only 
shown effective in a small study (mycophenolate 
mofetil) or not effective at all during the induction 
phase (cyclophosphamide) [69, 70]. Neurological 
involvement in pSS includes both the peripheral and 
central nervous systems. In many patients, neurologic 
symptoms precede the onset of other signs and 
symptoms of pSS [71, 72]. In general, intravenous 
corticosteroids are first-line therapy for patients with 
pSS associated neuropathy. Cyclophosphamide or 
intravenous immunoglobulins can be used in patients 
who do not improve with corticosteroids [72-74].  
By performing the ESSDAI in pSS patients on a 
regular basis, all the above discussed systemic 
manifestations can be recognized. pSS is also 
associated with hepatitis C (12%), autoimmune 
thyroid disease (10%), autoimmune chronic active 
hepatitis (2%) and primary biliary cirrhosis (5%), but 
the ESSDAI does not include these diseases [75, 76].  
Table 1. Systemic manifestations in primary Sjögren Syndrome. 
Domain Prevalence 
(%) 
Clinical manifestations Investigations 
Lymphadenopathy [51, 
52] 
10 persistent, unilateral salivary gland enlargement; lymphadenopathy; 
splenomegaly; skin vasculitis 
Serology, biological markers, 
biopsy 
Glandular [98] 30-50 firm, diffuse, nontender, swelling of mostly the parotid gland - 
Articular [57, 59] 50 Arthralgia; arthritis Radiography 
Skin [100-102] 23-67 Xerosis; Raynaud phenomenon; annular erythema, erythema nodosum; livedo 
reticularis; lichen planus; vitiligo; granuloma annulare; vasculitis 
Biopsy (if required) 
Lungs [60, 62, 63] 10-20 dry cough; nasal dryness; dyspnea,; interstitial lung disease Radiography, CT, pulmonary 
function 
Kidneys [66, 67, 103] 30 Distal renal tubular acidosis; nephrogenic diabetes insipidus; proximal tubular 
acidosis; hypokalemia 
Systematic renal tests, acid 
loading test, biopsy 
Muscles [104, 105] 44 Myalgia; muscle weakness; myositis Biopsy 
Peripheral nervous 
system [72, 106, 107] 
10 painful, burning dysesthesias in the distal extremities; sensory ataxic neuropathy; 
axonal sensorimotor polyneuropathy; mononeuritis multiplex; cranial 
neuropathies; radiculoneuropathy; autonomic neuropathy 
EMG 
 
Central nervous system 
[71, 108] 
20-25 motor or sensory deficits; seizures or cerebellar syndromes; psychiatric 
abnormalities; dementia and spinal cord involvement; subacute aseptic meningitis; 
chorea; optic neuritis; cognitive dysfunction 
EMG, MRI,  
CSF investigation, psychiatric 
analysis 
Haematological [29] 20 Normochromic, normocytic anemia; thrombocytopenia; mild leukopenia; 
lymphopenia 
Biochemical tests, bone marrow 
Biological [29, 109] 36-62 Hypergammaglobulinemia; hypogammaglobulinemia; hypocomplementia; 
cryoglobulinemia 
Serology and biological tests, 
bone marrow 
Abbreviations: EMG, Electromyography; CSF, cerebrospinal fluid; CT, Computed tomography; MRI, Magnetic resonance imaging;  
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pSS treatment requires a patient-specific 
approach that accounts for disease severity. In the 
Erasmus MC, we evaluate every pSS patient at least 
1-2 times a year. In addition to recording the patient’s 
self-reported symptoms and conducting a standard 
physical examination, we perform blood tests 
(including total blood count, liver and kidney tests, 
C3, C4 and IgG) and urinalysis to screen for organ 
involvement. In the case of mild disease activity (as 
measured by disease activity scores, ESSDAI), we do 
not perform additional invasive tests such as scans or 
functional tests (e.g. EMG, pulmonary function). In 
the case of self-reported symptoms or abnormal 
physical and/or laboratory examinations, additional 
testing for the presence (or change) of organ 
involvement is required. Also, patients with systemic 
immunosuppressive treatment or with increased 
organ involvement should be seen more frequently at 
the outpatient clinic (at least once every 3 months) to 
evaluate whether treatment is effective and potential 
side effects are tolerated. 
Diagnosis 
The diagnosis of pSS is based on the 
American-European consensus group (AECG) 
classification criteria for Sjögren syndrome [31] . 
These criteria include: 1) subjective presence of ocular 
dryness, 2) subjective presence of oral dryness, 3) 
objective measures of ocular dryness by Schirmer’s 
test or corneal staining, 4) focus score > 2 in a salivary 
gland biopsy, 5) salivary scintigraphy showing 
reduced salivary flow (1.5 mL in 15 minutes) and/or 
diffuse sialectasias and 6) positive autoantibodies 
against SS-A and/or SS-B. SS is diagnosed when 4 out 
of 6 items are present; either salivary gland pathology 
or the presence of autoantibodies against SS-A/SS-B is 
mandatory.The specific questions (criteria 1 and 2) 
should reveal whether eye and mouth symptoms are 
characteristic for pSS and additional tests should be 
performed. If pSS is suspected, laboratory 
investigations should be performed (e.g. markers for 
inflammation, systemic biochemical tests, serology 
and haematology) and the patient should be referred 
to an ophthalmologist for evaluation of ocular 
dryness. Recently, the American Group of 
Rheumatology (ACR) has developed new diagnostic 
criteria for pSS since the increasing use of (expensive) 
biologic agents should be based on more objective 
rather than subjective criteria [77]. The newly 
proposed criteria by the ACR differ from the AECG 
criteria by focussing more on objective measurements. 
Therefore, ocular and oral dryness are no longer part 
of the classification criteria. It remains unclear 
whether the new criteria are more sensitive than the 
AECG criteria. Based on a comparison study in 646 
subjects, the AECG criteria had an overall sensitivity 
in the general population of 88% compared to 83% of 
the ACR criteria. On all test characteristics (sensitivity, 
specificity etc.) the AECG criteria scores better 
compared to the ACR criteria, however, the results are 
not significantly different [78]. In conclusion, there is 
no clear evidence for increased value of the new ACR 
criteria over the old and familiar AECG criteria from 
the clinical or biological perspective [78]. Currently, 
the AECG criteria are still the most frequently used in 
clinical practice and research protocols. In Table 2, we 
summarize both sets of classification criteria [78]. 
Treatment 
Patients with pSS should be managed by a 
multidisciplinary team including at least a clinical 
immunologist/rheumatologist, ophthalmologist and 
dentist. Extensive clinical trials concerning the 
treatment of pSS are limited and thus, guidelines are 
lacking. Nowadays, multiple drugs are used in the 
treatment of pSS which can be divided in local and 
systemic therapy (Table 3).  
Preventive and local therapy 
Alcohol and smoking should be avoided and 
thorough oral hygiene is essential [79, 80]. 
Xeropthalmia can be managed with preservative-free 
teardrops and ocular lubricating ointments. Severe 
refractory dryness of the eyes can be treated with 
cyclosporin 0.05% [81]. Patients with xerostomia can 
manage the dry mouth by doing gustatory 
stimulation (chewing gum) and moisture 
replacement. 
Systemic treatment 
The majority of patients use pilocarpine, a 
muscarinic receptor agonist, which stimulates 
residual salivary gland function [82, 83]. Systemic 
treatment is indicated when: 1) general symptoms 
(e.g. arthralgia) cannot be managed with local 
treatment or adjustment of the patient’s lifestyle and 
2) in case of organ involvement. Non-steroidal 
anti-inflammatory drugs (NSAIDS) have beneficial 
effects on general symptoms, like arthralgia. When 
general symptoms become more chronic, 
hydroxychloroquine (HCQ) is indicated [84, 85]. It has 
been reported that patients with arthralgia benefit 
from HCQ [84]. A recent study shows, however, that 
fatigue does not improve by HCQ treatment [86]. In 
case of more severe organ involvement, other 
DMARDS or glucocorticoids should be added. 
 
Int. J. Med. Sci. 2017, Vol. 14 
 
http://www.medsci.org 
196 
Table 2. Comparison of the Revised American-European Consensus Group (AECG) Classification criteria and the American College of 
Rheumatology (ACR) Classification criteria for Sjögren's syndrome. 
# AECG ACR 
1 Ocular symptoms: a positive response to at least one of the following questions: 
Have you had daily, persistent, troublesome dry eyes for more than 3 months? 
Do you have a recurrent sensation of sand or gravel in the eyes? 
Do you use tear substitutes more than 3 times a day? 
 
2 Oral symptoms: a positive response to at least one of the following questions: 
Have you had a daily feeling of dry mouth for more than 3 months? 
Have you had recurrently or persistently swollen salivary glands as an adult? 
Do you frequently drink liquids to aid in swallowing dry food? 
 
3 Objective ocular signs - a positive result for at least one of the following two tests: 
Schirmer's I test, performed without anesthesia (≤5 mm in 5 minutes) 
Rose Bengal score or other ocular dye score (≥4 according to van Bijsterveld's scoring system) 
Keratoconjunctivitis sicca with ocular staining 
score ≥3  
4 Histopathology: in minor salivary glands (obtained through normal appearing mucosa) focal 
lymphocytic sialoadenitis, evaluated by an expert histopathologist, with a focus score ≥ 1, defined as 
number of lymphocytic foci (which are adjacent to normal-appearing mucous acini and contain more 
than 50 lymphocytes) per 4 mm2 of glandular tissue 
Labial salivary gland biopsy exhibiting focal 
lymphocytic sialadenitis with a focus score ≥1 
focus/4 mm2 
5 Salivary gland involvement: objective evidence of salivary gland involvement defined by a positive result 
for at least one of the following diagnostic tests: 
Unstimulated whole salivary flow (≤1.5 ml in 15 min) 
Parotid sialography showing the presence of diffuse sialectasias (punctate, cavitary or destructive 
pattern), without evidence of obstruction in major ducts 
Salivary scintigraphy showing delayed uptake, reduced concentration and/or delayed excretion of tracer 
 
6 Autoantibodies: presence in the serum of the following autoantibodies: 
 
Antibodies to Ro (SSA) and/or La (SSB) antigens 
Autoantibodies: presence in the serum of the 
following autoantibodies: 
 
Antibodies to Ro (SSA) and/or La (SSB) 
antigens 
Positive rheumatoid factor and ANA titer 
≥1:320 
  
Classification rules 
 pSS may be diagnosed when: 
The presence of any 4 of the 6 items is indicative of primary SS, as long as either item 4 (Histopathology) 
or 6 (Serology) is positive 
 
pSS may be diagnosed when: 
The classification of SS, which applies to 
individuals with signs/symptoms that may be 
suggestive of SS, will be met in patients who 
have at least 2 of the 3 objective features 
previously described 
 
 
Since methothrexate (MTX) is effective in RA, 
MTX is also used in the treatment of arthritis in pSS 
patients [87]. Glucocorticoid treatment is 
predominantly indicated when (severe) cutaneous, 
pulmonary, renal, musculoskeletal and/or 
neurological involvement occurs [88]. In case of 
insufficient effect of glucocorticoid therapy, 
glucocorticoid intolerance due to side effects and/or 
to reduce glucocorticoid dose, adding or switching of 
a DMARD (mycophenolate mofetil, cyclosporine A, 
azathioprine) should be considered. Therapy resistant 
pSS with proven organ damage is an indication to 
start biologicals, with the B cell as the most promising 
target based on the aetiology of pSS.  
Rituximab is a monoclonal antibody targeting 
the CD20 molecule (human B lymphocyte-restricted 
differentiation antigen) expressed on the surface of 
most B cells, including pre-B and mature B 
lymphocytes leading to B cell depletion [89]. Several 
studies have demonstrated a favourable effect of 
rituximab in pSS. Two studies combining 274 pSS 
patients reported that the severity of glandular, 
articular, renal, neurological, pulmonary and 
haematological involvement was significantly 
decreased in approximately 60% of the patients after 
six months [24, 90]. As a consequence of rituximab 
treatment, serum BAFF levels are increasing in order 
to stimulate B cell maturation, which can be countered 
by anti-BAFF treatment (belimumab) to achieve a 
longer B cell depletion and associated longer 
treatment effect [91]. Based on these findings and the 
pathophysiology of pSS, combination therapy with 
belimumab and rituximab would be an expensive but 
promising option [26]. The combination of rituximab 
and belimumab may be effective since this 
combination leads to an effective depletion of both the 
tissue and circulating B cells as well as a depletion of 
one of the stimulators (BAFF) required for B cell 
differentiation. Currently, new potential anti B cell 
therapies are being evaluated in (pre)clinical trials 
including anti-CD40 (decreases antigen presentation 
by B cells), anti-BAFF receptor (inhibits the effects of 
BAFF), anti-inducible costimulatory ligand (ICOSL, 
decreases activation of T-cells) and phosphoinositide 
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3-kinase delta inhibitor (PI3Kδ, inhibition of B cell 
development and activation) [92-95]. 
Prognosis 
Patients with pSS should be closely monitored to 
evaluate the development of systemic manifestations 
and the effects of treatment. Compared to the general 
population, pSS patients have an increased mortality 
risk. The standardized mortality ratio (ratio of 
observed deaths in the study group to expected 
deaths in the general population, SMR) of pSS 
patients is on average 2.86, showing that pSS has an 
impact on patients' survival [96, 97]. The leading 
cause of mortality in pSS is lymphoma with a 
lymphoma-specific SMR of 7.89, associating 
lymphoproliferative disorders directly with death in 
pSS [49]. However, once lymphoma is diagnosed, the 
prognosis is relatively favourable with a 15-year 
survival of almost 80% [98]. Other causes of death in 
pSS include vasculitis, renal failure due to 
glomerulonephritis and infections after the 
administration of immunosuppressive medication 
[69, 99]. Morbidity in pSS is mainly due to extreme 
fatigue and the presence of systemic manifestations 
and should be evaluated for each patient individually. 
Patients with systemic complications and lymphoma 
development have an increased mortality risk. 
Therefore, risk factors (clinical and biological) for 
lymphoma and other organ involvement (e.g. 
pulmonary function, renal function, neurological 
evaluation) should be assessed frequently.  
Conclusion 
This review summarizes the clinical aspects of 
pSS with special emphasis on the systemic 
manifestations. Physicians should be aware of pSS in 
patients presenting with sicca or general symptoms 
since the systemic manifestations are severe and are 
associated with increased morbidity and mortality. 
The treatment of pSS is effective and includes both 
local and systemic therapy. In recent years, changes in 
treatment of pSS have developed into a more 
organ-based approach, mainly due to the introduction 
of biologicals. Further research should focus on 
revealing new aetiological targets for therapy and to 
evaluate the effectiveness of current treatment 
protocols. 
 
Table 3. Overview of treatment options in primary Sjögren Syndrome. 
Drug Usual dose Main indications Main contra- 
indications 
Main side-effects Monitoring needed 
Systemic  
Pilocarpin [82, 83] 20-30mg/day orally Dryness of oral cavity Untreated 
cardiovascular 
condition, untreated 
asthma 
Headache, 
transpiration, frequent 
miction 
- 
NSAID [110, 111] 100-150 
mg/day, orally 
General symptoms (mainly 
arthralgia) 
Peptic ulcer, 
GI-bleeding, IBD, 
CHF, CVA, liver- or 
renal failure. 
GI effects, dizziness, 
rash, elevated liver 
enzyme test 
Six monthly: Blood count, 
systemic liver and kidney 
test. Cardiovascular risk 
profile 
Immunomodulatory   
Hydroxychloroquine 
[84, 85] 
200-400 
mg/day orally 
General symptoms (sicca, 
arthralgia and pain) 
Retinopathy, 
breastfeeding 
GI effects, rash, 
retinopathy, 
neuromyopathy 
Six monthly: blood count 
and muscular strength 
Yearly: complete eye 
examination by 
ophthalmologist 
Methotrexate [87] 10-20mg/week orally or 
intramuscular 
Add folate to prevent GI 
toxic  
effects 
Insufficient effect of HCQ on 
chronic complaints 
Liver and severe 
renal failure, severe 
respiratory failure, 
alcohol abuse, 
pregnant or lactating 
women 
GI effects, neutropenia, 
liver and renal toxicity, 
interstitial 
pneumonitis, alopecia 
3 monthly: blood count 
with differentiation, 
systemic liver and kidney 
test.  
Yearly: pulmonary 
function 
Glucocorticoids [64, 
112] 
20-40mg/day orally or 
intravenous 1g/day max. 3 
days 
Active systemic involvement 
(renal, pulmonary, 
neurological, muscular) 
Active infections 
(viral, fungal), ulcus 
ventriculi / duodeni  
Weight gain, 
hypertension, 
osteoporosis, diabetes, 
infection, 
neuropsychiatric 
reactions 
Next outpatient visit: 
Weight, arterial blood 
pressure, glycaemia, bone 
density 
Rituximab [24, 113] 1000mg intravenous; repeat 
after 2 weeks. 
30 minutes in prior: 100 mg 
methylprednisolone 
Active systemic involvement 
not responsive to non-biologic 
immunosuppressive drugs 
Pregnant or lactating 
women, active 
severe infection, 
severe CHF 
Infections, allergic 
reaction 
Next outpatient visit: 
Blood count with 
differentiation, systemic 
liver and kidney test. 
Abbreviations: GI, Gastrointestinal; IBD, inflammatory bowel disease; CHF, congestive heart failure; CVA, cerebrovascular accident. 
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